Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Therapix Biosciences Ltd ADR TRPXY

Healthcare Biotechnology
Therapix Biosciences Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several innovative immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The operating segments of the group are Development of drugs based on cannabinoid... see more

Recent & Breaking News (OTCPK:TRPXY)

CURE Pharmaceutical & Therapix Biosciences Signs MOU with Israel's Assuta Medical Center to Develop First-in-Class Therapeutic Products in Fields of Personalized Medicine & Cannabinoids

PR Newswire July 11, 2017

Therapix Biosciences to Ring the Nasdaq Stock Market Opening Bell on June 28

PR Newswire June 27, 2017

Therapix Biosciences to Present at Upcoming Scientific and Investor Conferences in June

PR Newswire May 30, 2017

Therapix Biosciences Announces CEO Change

PR Newswire May 24, 2017

Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome

PR Newswire May 8, 2017

Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer

PR Newswire May 3, 2017

Therapix Signs Exclusive License Agreement with Yissum for Nasal Drug Delivery Technology

PR Newswire April 5, 2017

Therapix Biosciences Ltd. Announces Full Exercise of Underwriters' Over-Allotment Option

PR Newswire April 3, 2017

Therapix Biosciences Ltd. Announces Closing of U.S. Initial Public Offering of American Depositary Shares; 2,000,000 American Depository Shares Priced at $6.00 per ADS

PR Newswire March 27, 2017

The Legal Cannabis Market Developments in 2017

PR Newswire March 27, 2017

Therapix Biosciences Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing

PR Newswire March 22, 2017